NuSil Technology LLC recently announced the appointment of Ernest Waaser as its new CEO. Waaser brings more than 30 years of experience in leading numerous public and privately held healthcare companies. He takes over from NuSil’s co-founder and CEO, Dick Compton, who is retiring as CEO but will continue to serve as chairman of the Board of Directors.
Prior to NuSil, Waaser was an operating partner at Linden Capital Partners; previous to that, he served as CEO of Systagenix Wound Management, a private equity-backed spinout of Johnson & Johnson’s advanced wound care unit, where he led the business through a period of growth resulting in a sale to Kinetic Concepts Inc.
“We are thrilled to have an executive of Ernest’s caliber join the NuSil team,” said Matt Holt, a member of the Board of Directors and managing director at New Mountain Capital, NuSil’s majority shareholder. “With his proven track record of growing global med-tech businesses, we believe he is absolutely the right person to lead NuSil through its next phase of growth and expansion. Our ability to recruit this kind of talent speaks to the outstanding job that Dick Compton and the management team have done in building an exciting, growth-oriented environment at NuSil. Dick is a true icon in the specialty silicone industry and we are pleased that he will continue as Chairman of the Board.”
For more information, visit www.nusil.com.